Abstract:ABSTRACT Both human and non-human simian adenoviruses (HAdVs and SAdVs, respectively) have been used as gene therapy and vaccine vectors. The high prevalence of HAdVs and the neutralizing antibodies associated with prior infection, may limit HAdV-based vector use in human subjects. To overcome this drawback, a vector derived from a newly isolated and characterized macaque adenovirus was constructed. SAdVs (33.9%) were screened from 115 SAdV fecal samples collected at a zoological park. One novel SAdV was isolated and the whole genome was sequenced and analyzed. The pre-existing neutralizing antibody levels were very low against this isolate (10%). Interestingly, SAdV vector constructs that lack E3 region could not produce infectious progeny in HEK293 cells, suggesting that the E3 region is necessary for SAdV replication. The absence of E3 region could be compensated for by replacement with HAdV-5 E4orf6; the resultant construct could replicate well in HEK293 cells. The enhanced Green Fluorescent Protein (eGFP) was inserted into SAdV E3 region and expressed at high level. One-step growth curve showed that the replication of the SAdVs with HAdV-5 E4orf6 substitution and E1/E3 deletion was similar to that of wild-type SAdVs in HEK293 cells, but the modified SAdVs were replication-deficient in A549 cells which lack HAdV-5 E1A and E1B. Finally, we demonstrated that GZ3-12 could infect cells expressing hCAR or hDSG2 receptors. The successful isolation, characterization, and modification of novel SAdVs provide a potentially important vaccine and gene therapy candidate and a new strategy for the rapid acquisition and development of non-HAdV-based alternative vectors for human health applications. Adenoviruses are widely used in gene therapy and vaccine delivery. Due to the high prevalence of human adenoviruses (HAdVs), the pre-existing immunity against HAdVs in humans is common, which limits the wide and repetitive use of HAdV vectors. In contrast, the pre-existing immunity against simian adenoviruses (SAdVs) is low in humans. Therefore, we performed epidemiological investigations of SAdVs in simians and found that the SAdV prevalence was as high as 33.9%. The whole-genome sequencing and sequence analysis showed SAdV diversity and possible cross species transmission. One isolate with low level of pre-existing neutralizing antibodies in humans was used to construct replication-deficient SAdV vectors with E4orf6 substitution and E1/E3 deletion. Interestingly, we found that the E3 region plays a critical role in its replication in human cells, but the absence of this region could be compensated for by the E4orf6 from HAdV-5 and the E1 expression intrinsic to HEK293 cells.

[Monocytes Are More Susceptible in Vitro in Rhesus Macaques of Chinese Origin to Recombinant Serotype 5 Adenovirus with Higher Preexisting Vector Specific Neutralizing Antibody Titer].

Circumventing Antivector Immunity by Using Adenovirus-Infected Blood Cells for Repeated Application of Adenovirus-Vectored Vaccines: Proof of Concept in Rhesus Macaques

Isolation of novel simian adenoviruses from macaques for development of a vector for human gene therapy and vaccines

Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews

Mucosal Trafficking of Vector-Specific Cd4(+) T Lymphocytes Following Vaccination of Rhesus Monkeys with Adenovirus Serotype 5

Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.

An Adenovirus-Vectored COVID-19 Vaccine Confers Protection from SARS-COV-2 Challenge in Rhesus Macaques.

High-Throughput Screening for the Prevalence of Neutralizing Antibodies against Human Adenovirus Serotype 5

Efficacy of Multivalent Adenovirus-Based Vaccine Against Simian Immunodeficiency Virus Challenge.

Evaluation of HCMV Vaccines in Rhesus Macaques by a Novel Micro-Neutralization Assay (113.4)

Infecting Human Dendritic Cells with Ad5-EGFP Recombinant Adenovirus Vectors

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011

Epidemiology of Adenovirus Type 5 Neutralizing Antibodies in Healthy People and AIDS Patients in Guangzhou, Southern China.

Preparation and Identification of Monoclonal Antibodies Against the Adenovirus Vector

[Anti-Adenovirus Neutralizing Antibodies and Gag-specific Cellular Immune Responses in Macaca Fascicularis Immunized with Ad5-HIVgag].

A Mucosal Adenovirus Prime/Systemic Envelope Boost Vaccine Regimen Elicits Responses in Cervicovaginal and Alveolar Macrophages of Rhesus Macaques Associated With Delayed SIV Acquisition and B Cell Help

Preexisting Virus-Specific T Lymphocytes-Mediated Enhancement of Adenovirus Infections to Human Blood CD14+ Cells

Lung-Targeted Transgene Expression of Nanocomplexed Ad5 Enhances Immune Response in the Presence of Preexisting Immunity

HIV vaccine candidates generate in vitro T cell response to putative epitopes in Chinese-origin rhesus macaques.

Comparative Immunogenicity In Rhesus Monkeys Of Dna Plasmid, Recombinant Vaccinia Virus, And Replication-Defective Adenovirus Vectors Expressing A Human Immunodeficiency Virus Type 1 Gag Gene